Risk classification of life and health insurance applicants with atypical melanocytic hyperplasia or malignant melanoma in situ

R. F. Wagner, C. M. Murphy

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Physicians may attempt to disguise malignant melanoma in situ from insurance companies by diagnosing atypical melanocytic hyperplasia instead. This study indicates that the insurance industry is not misled by atypical melanocytic hyperplasia and treats it equivalently to malignant melanoma in situ. In addition, physicians' failure to diagnose malignant melanoma in situ may result in underestimation of the incidence of malignant melanoma and may cause inadequate initial treatment and patient follow-up.

Original languageEnglish (US)
Pages (from-to)352-354
Number of pages3
JournalCutis
Volume50
Issue number5
StatePublished - Jan 1 1992

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Risk classification of life and health insurance applicants with atypical melanocytic hyperplasia or malignant melanoma in situ'. Together they form a unique fingerprint.

  • Cite this